| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leader |
1 Haematology Department, 3rd Floor, Macewen Building, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, UK
Dr Walker email: idw{at}idwhaem.demon.co.uk Thrombophilia can be defined as a predisposition to thrombosis. Abnormalities in haemostasis that are associated with clinical thrombophilia include heritable defects, such as mutations in the genes encoding the natural anticoagulants antithrombin, protein C, and protein S, or clotting factors prothrombin and factor V, and acquired defects, such as antiphospholipids. Women with thrombophilic defects have been shown to be at increased risk, not only of pregnancy associated thromboembolism, but also of other vascular complications of pregnancy, including pre-eclampsia and fetal loss. Routine thrombophilia screening of all women attending antenatal clinics is not recommended. Because some thrombophilic defects—for example, type 1 antithrombin deficiency and antiphospholipids—are associated with a high risk of recurrent thrombosis or other pregnancy complications, it is suggested that selected women (those with a personal or confirmed family history of venous thromboembolism or with a history of recurrent fetal loss) are screened for these defects to allow pregnancy management planning.
Key Words: thrombophilia • pregnancy
This article has been cited by other articles:
|
|
 |
|
  J. N. Quinones, D. N. James, D. M. Stamilio, K. L. Cleary, and G. A. Macones Thromboprophylaxis After Cesarean Delivery: A Decision Analysis Obstet. Gynecol., October 1, 2005; 106(4): 733 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.V. N. Menon, V. Shah, and P. S. Kamath The Budd-Chiari Syndrome N. Engl. J. Med., February 5, 2004; 350(6): 578 - 585. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dossenbach-Glaninger, M. van Trotsenburg, M. Dossenbach, C. Oberkanins, A. Moritz, W. Krugluger, J. Huber, and P. Hopmeier Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and Coagulation Factor XIII Val34Leu Polymorphism: Impaired Fibrinolysis and Early Pregnancy Loss Clin. Chem., July 1, 2003; 49(7): 1081 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Harada, H. Morita, Y. Imai, D. Hayashi, N. Takeda, K. Maemura, Y. Yazaki, and R. Nagai Deficiency of Protein S-Mediated Familial Venous Thrombophilia: A Case Report Angiology, May 1, 2003; 54(3): 377 - 381. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Kanayama, K. Takahashi, T. Matsuura, M. Sugimura, T. Kobayashi, N. Moniwa, M. Tomita, and K. Nakayama Deficiency in p57Kip2 expression induces preeclampsia-like symptoms in mice Mol. Hum. Reprod., December 1, 2002; 8(12): 1129 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.M. Rahman and J. Wendon Severe hepatic dysfunction in pregnancy QJM, June 1, 2002; 95(6): 343 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Prasmusinto, S. Skrablin, C. Hofstaetter, R. Fimmers, and K. van der Ven The Methylenetetrahydrofolate Reductase 677 C->T Polymorphism and Preeclampsia in Two Populations Obstet. Gynecol., June 1, 2002; 99(6): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Donohoe, S Quenby, I Mackie, G Panal, R Farquharson, R Malia, J Kingdom, and S Machin Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal andheparin-treated antiphospholipid syndrome pregnancies Lupus, January 1, 2002; 11(1): 11 - 20. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
